On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference
miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1% African authority on malaria diagnosis said "miLab is a potential game changer in accelerating access to parasitological confirmation" YONGIN, South Korea, April 25, 2024 /PRNewswire/ -- Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced that the results of a clinical performance study of its malaria diagnostic solution showed a s
April 26, 2024